Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026 - ResearchAndMarkets.com
The "Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026" report has been added to ResearchAndMarkets.com's offering.
The "Chronic
Obstructive Pulmonary Disease Forecast and Market Analysis to 2026"
report has been added to ResearchAndMarkets.com's
offering.
Chronic obstructive pulmonary disease (COPD) is a leading cause of
morbidity and mortality worldwide. In 2004, it was the fourth most
common cause of death in the world, and it is projected to be the third
most common cause of death by 2030. COPD is characterized by diminished
lung function, and is often accompanied by respiratory symptoms
including chronic productive cough, wheezing, and dyspnea (shortness of
breath). The most prominent risk factor for COPD worldwide is cigarette
smoking. COPD is more common in men and the elderly, driven by long-term
exposure to risk factors and the irreversible progression of COPD over
time.
Market Snapshot
-
The COPD market will continue to grow due to the success of
combination therapies. -
Significant unmet need remains for novel therapies that prevent COPD
disease progression in addition to providing symptomatic improvement. -
An increase in the total COPD population is predicted in all included
markets due to aging populations. -
Paleontologists excited about the arrival of triple therapies as they
will simplify disease management. -
AstraZeneca's triple therapy PT010 will strengthen its franchise,
allowing it to offer a comprehensive treatment option. -
Payers are likely to demand favorable pricing for new combination
LABA/LAMAs and triple combination ICS/LABA/LAMA inhalers.
Key Topics Covered:
FORECAST: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on 31
July 2018)
Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Advair
Product Profile: Anoro Ellipta
Product Profile: Arcapta Neohaler
Product Profile: Bevespi Aerosphere
Product Profile: Breo Ellipta
Product Profile: Daliresp
Product Profile: Duaklir Pressair
Product Profile: Incruse Ellipta
Product Profile (Late Stage): Pt010
Product Profile: Seebri Neohaler
Product Profile: Spiriva
Product Profile: Stiolto Respimat
Product Profile: Striverdi Respimat
Product Profile: Symbicort
Product Profile: Trelegy Ellipta
Product Profile: Trimbow
Product Profile: Tudorza Pressair
Product Profile: Utibron Neohaler
TREATMENT: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on
31 July 2018)
Overview
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Unmet Needs In Chronic Obstructive Pulmonary Disease
Pipeline Drugs And Future Treatment
EPIDEMIOLOGY: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published
on 22 January 2019)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
MARKETED DRUGS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published
on 31 July 2018)
Overview
Product Overview
Product Profile: Advair
Product Profile: Anoro Ellipta
Product Profile: Arcapta Neohaler
Product Profile: Bevespi Aerosphere
Product Profile: Breo Ellipta
Product Profile: Daliresp
Product Profile: Duaklir Pressair
Product Profile: Incruse Ellipta
Product Profile: Seebri Neohaler
Product Profile: Spiriva
Product Profile: Stiolto Respimat
Product Profile: Striverdi Respimat
Product Profile: Symbicort
Product Profile: Trelegy Ellipta
Product Profile: Trimbow
Product Profile: Tudorza Pressair
Product Profile: Utibron Neohaler
COPD PRICING, REIMBURSEMENT, AND ACCESS (Published on 11 May
2016)
Overview
Executive Summary
Market Context
Global Payer And Key Opinion Leader Insights
Us Pricing
Us Payer Insights
Us Reimbursement
Japan
Five Major Eu Markets Pricing
Five Major Eu Markets Payer Insights
Generic Ics/Laba Inhalers In The Five Major Eu Markets
France
Germany
Italy
Spain
UK
Methodology
PIPELINE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (Published on 31
July 2018)
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Nucala
Product Profile (Late Stage): Pt010
Product Profile (Late Stage): Revefenacin
For more information about this report visit https://www.researchandmarkets.com/r/mwxhiv
View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005760/en/